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Abstract 
Chorea-Acanthocytosis (ChAc) is a devastating, little understood, and currently untreatable neurodegenerative 
disease caused by VPS13A mutations. Based on our recent demonstration that accumulation of activated Lyn tyrosine 
kinase is a key pathophysiological event in human ChAc cells, we took advantage of Vps13a−/− mice, which pheno-
copied human ChAc. Using proteomic approach, we found accumulation of active Lyn, γ-synuclein and phospho-tau 
proteins in Vps13a−/− basal ganglia secondary to impaired autophagy leading to neuroinflammation. Mice double 
knockout Vps13a−/−  Lyn−/− showed normalization of red cell morphology and improvement of autophagy in basal 
ganglia. We then in vivo tested pharmacologic inhibitors of Lyn: dasatinib and nilotinib. Dasatinib failed to cross the 
mouse brain blood barrier (BBB), but the more specific Lyn kinase inhibitor nilotinib, crosses the BBB. Nilotinib ame-
liorates both Vps13a−/− hematological and neurological phenotypes, improving autophagy and preventing neuroin-
flammation. Our data support the proposal to repurpose nilotinib as new therapeutic option for ChAc patients.
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Introduction
The ultra-rare neurodegenerative disease Chorea-Acan-
thocytosis (ChAc) with 1000–5000 cases worldwide is 
one of the core neuroacanthocytosis syndromes (NA) [26, 
50, 70]. NA diseases manifest with a spectrum of neu-
rological symptoms in addition to the presence of mis-
shaped red blood cells (RBCs) with thornlike protrusions, 
referred to as acanthocytes [7, 26, 35, 50]. Autosomal-
recessive ChAc is caused by loss-of-function mutations 
in the vacuolar protein sorting 13 homolog A (VPS13A) 
gene encoding the chorein polypeptide gene product 
[8, 10, 54, 68]. Only symptomatic treatment is currently 
available to modify the devastating disease course [71] 
despite a shortened life-span marked by considerable 
morbidity and compromised independent living. These 
clinical manifestations are accompanied by loss of stri-
atal medium spiny neurons [38] and a distinctive cortical 
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neurodegeneration [39]. Other members of the vacuolar 
protein sorting (Vps) family of proteins have been linked 
to more common neurodegenerative disorders such as 
Parkinson’s disease (PD) (Vps35 and Vps13c) and fronto-
temporal dementia (Vps4B) [34, 60].
ChAc patients often present with progressive move-
ment disorders like chorea, parkinsonism and/or dysto-
nia [13, 53, 70]. Therefore, ChAc should be considered as 
a relevant differential diagnosis of Huntington’s disease 
(HD) [22]. This disease severely affects independent liv-
ing, and results in significant morbidity and a markedly 
reduced life-span [71].
Although studies in mammalian cell lines and in model 
organisms such as yeast suggest that chorein’s possible 
function as a lipid transporter at organelle contact sites, 
possibly mediating non-vesicular phospholipid transport 
[14, 32, 74], the function of chorein remains incompletely 
understood. We recently identified accumulation of 
active Lyn, a kinase of the Src family tyrosine kinases as 
key driver of ChAc pathophysiology (for review see [50]). 
We also found that Lyn inhibition by PP2 or dasatinib 
(1) ameliorates the distorted erythroid morphology and 
other altered red cell features in  vitro; and (2) amelio-
rates the pathologically increased synaptic transmission 
in striatal medium spiny neurons generated from ChAc 
iPSCs [9, 42, 64]. The proteotoxic effect of Lyn gain-of-
function reflects impaired autophagy, in agreement with 
VPS13A-deficient cell models.
Here, we studied  Vps13a−/− mice lacking chorein. 
 Vps13a−/− mice display biological features of human 
ChAc. We confirmed the accumulation of active Lyn in 
both RBCs and basal ganglia of  Vps13a−/− mice, associ-
ated with impaired autophagy and accumulation of phos-
pho-Tau proteins and γ-synuclein. Dasatinib treatment of 
 Vps13a−/− mice blocked Lyn activity in RBCs but not in 
the basal ganglia. Mass spectrometric analysis revealed 
that dasatinib did not accumulate to detectable levels in 
basal ganglia, thus providing one potential explanation 
for the absence of an effect of dasatinib on neurologic 
phenotype of ChAc patients. We therefore tested the 
second generation TKI nilotinib, with higher selectivity 
for Lyn and able to cross the blood–brain barrier (BBB) 
[21]. We showed that nilotinib reached the basal ganglia, 
where it inhibited Lyn and improved autophagy, neuronal 
loss and neuroinflammation.
Materials and methods
Mouse model for ChAc  (Vps13a−/− mice)
Experiments were performed on age and gender- 
matched WT (C57BL/6J) and  Vps13a−/− mice and on 
12  months-old sex-matched  Vps13a−/−Lyn−/− mice. 
We obtained Vps13a heterozygous knock out (±) mice 
from the EMMA Consortium (Additional file 1: Fig. S1). 
 Vps13a−/−Lyn−/− mice were generated in house back-
crossing for at least 16 generation  Vps13a−/− mice and 
 Lyn−/− mice. The Institutional Animal Experimental 
Committee of University of Verona (CIRSAL) approved 
the experimental protocol. Whenever indicated WT 
and  Vps13a−/− mice were daily treated with vehicle (tap 
water) or dasatinib or nilotinib. Dasatinib (50  mg/Kg) 
was administered by daily gavage to 12 months-old mice 
for 1 month. Nilotinib (25 mg/Kg/day) was administered 
by gavage to 11  months-old  Vps13a−/− mice for either 
6 weeks or 3 months or 6 months. This dosage was cho-
sen based on a previous report on a mouse model for PD 
and AD [20, 40]. Isoflurane-anesthetized mice were ran-
domly assigned to experimental groups and blindly ana-
lyzed. Hematologic parameters and red cell indices were 
evaluated on a Siemens ADVIA 2120 hematology ana-
lyzer. Hematocrit and hemoglobin were manually deter-
mined [27, 43, 44]. Acanthocyte evaluation and counting 
were performed on McGrawald-Giemsa-stained blood 
smears and by electron microscopy [42]. Brains imme-
diately removed from euthanized mice were dissected to 
isolate basal ganglia (BG) and cortex tissues, which were 
instantly frozen in liquid nitrogen.
Statistical analysis
Statistical analysis was performed with the GraphPad 
Prism 8.0 program. Data were analyzed using either t-test 
or one-way ANOVA (Dunnet’s test) for longitudinal 
studies or 2-way analysis of variance (ANOVA) with Bon-
ferroni connection for repeated measures among mice of 
different genotypes. p < 0.05 was considered significant.
Behaviour test
Comparisons between two groups were performed 
using the two-tailed unpaired Student’s t-test. Data were 
expressed as the mean ± SEM. Statistical significance was 
accepted at the 95% confidence level (p < 0.05). Sponta-
neous locomotor activity was evaluated using a two-way 
mixed-model ANOVA (strain*day) followed by the Bon-
ferroni post hoc test. For the analysis of gait parameters, 
the means of the hind and front paws and individual paws 
were considered. The individual averages for each mouse 
were calculated over three good runs (straightforward 
and without hesitations), and the differences between 
groups were evaluated with a two-tailed unpaired Stu-
dent’s t-test. Statistical significance was accepted at the 
95% confidence level (p < 0.05).
Immunofluorescence microscopy
Quantification of NeuN positive cells and Iba1 positive 
cells was followed by statistical analyses applying two-
tailed Unpaired t test. Data are shown as mean ± SEM. 
Page 3 of 15Peikert et al. acta neuropathol commun            (2021) 9:81  
Quantification of beclin1-positive and γ-Synuclein-
positive cells were followed by a statistical analysis. 
Statistically significant differences between the two non-
parametric data sets were assessed by Mann–Whitney’s 
test. Statistical significance was determined at p < 0.05.
Brain spectroscopy
Comparisons between two groups were performed 
using the two-tailed unpaired Student’s t-test. Data were 
expressed as the mean ± SEM. Statistical significance was 
accepted at the 95% confidence level (P < 0.05).
NanoLC/MS–MS analysis
Statistical analysis was performed in MeV using a Stu-
dent’s two tailed t-test. Statistical significance was deter-
mined at P < 0.05.
Results
Vps13a−/− mice recapitulate key features of patients 
suffering from ChAc
Survival of  Vps13a−/− mice was significantly reduced 
compared to wild-type animals as assessed by log-rank 
test analysis (Additional file  1: Fig. S1.2A). Weights of 
both male and female Vps13a−/− mice of across all ages 
were lower than those of wild-type animals (Additional 
file 1: Fig. S1.2B).
Fig. 1 Vps13a−/− mice exhibit hematologic and neurologic features similar to those in human ChAc. a Left panel. Western blot (Wb) analysis of 
chorein in red cells of WT and  Vps13a−/− mice. Catalase served as protein loading control. Lower panel. Densitometric analysis (arbitrary units) 
of immunoblot bands like those shown; means ± SEM (n = 6; *p < 0.001 vs. WT by t-test). Right panel (from left to right). Morphologic analysis of 
peripheral blood from wild-type (WT) and  Vps13a−/− mice. Blood smears stained with May-Grunwald-Giemsa. Cells were imaged under oil at 
100 × magnification using Panfluor objective 1.30 numeric aperture on a Nikon Eclipse DS-5 M camera and processed with Digital Slide (DS-L1) 
Nikon. Black arrows indicate acanthocytes in  Vps13a−/− mice. (see also Additional file 1: Fig. S4.2C). Electron microscopy of circulating red cells from 
 Vps13a−/− mice. The image is representative of 10 similar imaged visual fields for each of 10  Vps13a−/− mice at the ages of 12 months. b Western 
blot (Wb) analysis of Chorein in isolated basal ganglia of wild-type (WT) and  Vps13a−/− mice. GADPH is the loading control. Densitometric analysis 
(arbitrary units) of the immunoblot bands similar to those shown are presented (bottom); data are means ± SEM (n = 6; *P < 0.001 vs. WT by t-test). c 
Spontaneous locomotor activity in  Vps13a−/− and wild-type mice in undisturbed conditions. At 12 months mice were maintained in a PhenoTyper® 
cage (Noldus®) and continuously monitored for two consecutive days (Day 1 and Day 2). Data represent the mean ± SEM of the total distance 
moved (cm) per day (**P < 0.01 vs. wild-type mice, n = 6 animals per group). d CatWalk® gait analysis of  Vps13a−/− and wild-type mice. The data 
represent the mean ± SEM of three runs per animal and are presented per each paw, left front (LF), left hind (LH), right front (RF) and right hind (RH) 
(*p < 0.05, **P < 0.01, ***P < 0.001; n: 19  Vps13a−/− mice, n: 15 wild-type mice) (see also Additional file 1: Fig. S5A). At 18 months of age  Vps13a−/− 
mice showed a deviating paw angle of both hind paws compared to controls *P < 0.05; n = 19  Vps13a−/− mice, n = 15 wild-type mice)
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Hematologic phenotype
Chorein expression was undetectable in  Vps13a−/− 
mouse RBCs (Fig.  1a). Acanthocytes were observed by 
multiple imaging approaches (Fig.  1a). The numbers of 
acanthocytes in Vps13a−/− mice were stable beyond age 
2 months, considered as adult subjects from the perspec-
tive of hematologic development (Additional file  1: Fig. 
S1.2C). No major differences in hematologic parameters 
or red cell indices were observed in  Vps13a−/− mice 
compared to wild-type animals with the exception of the 
Hb distribution width (HDW), useful to evaluate acan-
thocytes (Table  1). HDW was significantly increased 
in  Vps13a−/− mice compared to wild-type animals 
(Table 1). We fractionated RBCs as a function of cell Hb 
content and cell volume (V/HC), revealing a dense cell 
fraction only in  Vps13a−/− mice (Additional file  1: Fig. 
S1.2C, lower panel, blue circle). This fraction contains 
acanthocytes similarly to those observed in human ChAc 
[42]. As like human ChAc, osmotic fragility of  Vps13a−/− 
mouse RBCs was higher than in wild-type RBCs (Addi-
tional file 1: Fig. S1.2D). This was associated with reduced 
 K+ content in Vps13a−/− RBCs as compared to healthy 
mouse RBCs (WT mice 460 ± 12  mmol/Kg Hb vs. 
Vps13a−/− mice 350 ± 8.1  mmol/Kg Hb n = 6 in each 
group, *p < 0.05), resembling again the human disease [5].
In  Vps13a−/− mouse RBCs, we found accumulation of 
active Lyn compared to wild-type erythrocytes (Addi-
tional file  1: Fig. S1.2E). This increase was associated 
with retention of double membrane remnants and vesi-
cles, indicating an impairment of autophagy (Fig. 1a). In 
agreement with the morphological findings, we observed 
accumulation of Ulk1, Atg4, Atg5 and Rab5 polypeptides, 
as seen in human ChAc RBCs [42] (Additional file 1: Fig. 
S1.2F). Taken together these data recapitulate key hema-
tologic features of ChAc patients.
Neurologic phenotype
Chorein was undetectable in isolated basal ganglia from 
saline buffer-perfused 12- and 18-months old Vps13a−/− 
mice (Fig.  1b). Gait and motor assessment were per-
formed in cohorts of  Vps13a−/− (n:19) and wild-type 
(n:15) mice at 12 and 18 months. Anxiety trait and spon-
taneous locomotor activity were assessed in a subgroup 
(n:6 for each strain) of both mouse strains (12  months-
old only) applying a 5-min protocol using elevated-plus 
maze (EPM). No significant differences were found in the 
time spent in the closed and open arms (an index related 
to a more or a less anxiety trait) between  Vps13a−/− and 
wild-type mice. The spontaneous locomotor activity was 
continuously monitored for two days by video-track-
ing observations of individual 12  months-old mice in 
PhenoTyper cages, which allowed home-cage evalua-
tion of locomotor activity, unaffected by anxiety and/or 
stress of a test cage environment. The overall distance 
covered by the  Vps13a−/− mice was significantly higher 
(day 1: 82.48 ± 11.68%, p < 0.01; day 2: 100.29 ± 11.68%, 
p < 0.01) compared to that of age-matched wild-type mice 
(Fig.  1c).  Vps13a−/− mice and matched wild-type mice 
were tested for their spontaneous gait behavior (Fig. 1d). 
The gait performance of  Vps13a−/− mice was affected 
during the test session at both 12 and 18 months of age. 
In particular, starting from 12  months,  Vps13a−/− mice 
showed a longer duration from the start of a run until 
maximum contact occurs for both hind paws compared 
to age- and weight-matched control mice (see also Addi-
tional file 1: Fig. S2A for schematic diagram of the angle 
evaluation). The delay in reaching the maximum con-
tact of paws with a glass plate was also observed at older 
age (Fig.  1d). Also, at 18  months, but not at 12  months 
(Fig.  1d),  Vps13a−/− mice showed a different paw angle 
of both hind paws (Fig. 1d). A similar discrepancy in paw 
angle was reported in a transgenic rat model for Hun-
tington’s disease [69]. “Max contact at (%)” refers to the 
duration, from the start of a run, until maximum con-
tact of paws occurs. This index has been largely studied 
in rodent models in the context of parkinsonism [2, 3]. 
The basal ganglia of these aged Vps13a−/− mice exhib-
ited accumulation of active Lyn as compared to wild-type 
animals (Additional file 1: Fig. S2B, C), in agreement with 
our previous report on active Lyn accumulation in neu-
ronal cells derived from ChAc iPSC [64]. We note, in par-
ticular the presence in Vps13a−/− mouse basal ganglia of 
active Lyn stabilized in high molecular weight complexes, 
as earlier observed in human ChAc RBCs (Additional 
file 1: Fig. S2D) [42]. Collectively, our data indicate that 
Vps13a−/− mice recapitulate biological features and neu-
rological phenotype like those of ChAc patients.
Table 1 Hematological parameters and red cell indices in wild-
type and  Vps13a−/− mice
Hct haematocrit, Hb haemoglobin, MCV mean corpuscular volume, MCH mean 
corpuscular haemoglobin, CHCM cell hemoglobin mean content, RDW red cell 
distribution width, HDW hemoglobin distribution width, Retics reticulocytes 





Hct (%) 45.3 ± 1.2 46.1 ± 0.8
Hb (g/dl) 14.9 ± 0.3 14.2 ± 0.6
MCV (fl) 52.4 ± 1.6 53.1 ± 1.5
MCH (pg) 16.3 ± 0.8 15.9 ± 0.8
CHCM (g/dL) 26.3 ± 0.2 26.2 ± 0.2
RDW (%) 12.5 ± 0.4 12.9 ± 0.7
HDW (g/dL) 2.1 ± 0.43 3.1 ± 0.47*
Retics (cell/uL) 417 ± 65 382 ± 84
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Vps13a−/− mice show neuronal loss 
and neuroinflammation
To explore neurochemical abnormalities in striatum from 
 Vps13a−/− mice by non-invasive approaches, we used 
proton magnetic resonance spectroscopy H-MRS [1, 11, 
31]. We found a significant reduction in N-acetylasparate 
(NAA) in striatum from  Vps13a−/− mice compared to 
wild-type animals, suggesting the presence of neuronal 
degeneration in mice genetically lacking Chorein (Fig. 2a) 
[11, 51]. Histopathological studies of  Vps13a−/− mice 
demonstrated a significant reduction in NeuN staining in 
cortex compared to wild-type animals, indicating a loss 
of neurons (Fig. 2b).
It is noteworthy that we found increased microglia in 
the cortex from 12  months-old  Vps13a−/− mice com-
pared to wild-type animals (Fig. 2c). This was associated 
with increased activation of NF-kB p65 in both cortex 
and basal ganglia from 12 and 18 months-old  Vps13a−/− 
mice compared to wild-type animals, consistent with 
neuroinflammation in mice genetically lacking Chorein 
(Fig. 2d, see also Additional file 1: Fig. S3). In agreement 
with this observation, we noted up-regulation of IL-1β 
mRNA expression in both cortex and basal ganglia from 
12 and 18 months-old  Vps13a−/− mice compared to wild-
type animals (Fig. 2e).
Taken together, our data indicate neuron loss and 
neuro-inflammation in Vps13a−/− mice, highlighting 
similarities with other neurodegenerative diseases such 
as Parkinson disease [23].
Vps13a−/− mice show impaired autophagy involving 
beclin-1 pathway
To understand the possible contribution of 
impaired autophagy to neuronal dysfunction and 
Fig. 2 Vps13a−/− mice show neuronal loss associated with signs of neuroinflammation. a N-Acetyl Aspartate (NAA) concentration determined 
by 1H MRS (7 T) in the striatum of  Vps13a−/− or WT control mice at different age (7, 12 and 18 months). NAA concentration was normalized using 
creatine as internal reference. Data are mean ± SEM (*p < 0.05 by t-test vs. WT). b Representative images of NeuN staining in cortex of WT control 
and  Vps13a−/− mice at 12 months of age. Neurons in green, nuclei in blue. Scale bar: 50 mm (Objective 20x). Quantification of NeuN-positive cells 
area in cortex. Results are expressed as mean ± SEM. c Representative images of Iba-1 positive microglia cells in cortex of WT control and  Vps13a−/− 
mice at 12 months of age (Microglia in red, nuclei in blue). Scale bar:50 mm. Quantitative analysis of microglia show significant differences in 
microglial density and activation in the cortex of  Vps13a−/− compared to WT control mice. Results are expressed as mean ± SEM (****P < 0.0001; 
Unpaired t-test) d Western blot (Wb) analysis of phospho-NF-kB and total NF-kB in isolated basal ganglia of wild-type (WT) and Vps13a−/− mice 
at 12 and 18 months (Mo) of age. GADPH is the loading control. Densitometric analysis is shown in Additional file 1: Fig. S6. e mRNA expression 
of interleukine-1β (Il-1b) by qRT-PCR on cortex and basal ganglia from 12 and 18 months (Mo) old WT and Vps13a−/− mice. Experiments were 
performed in triplicate. Data are mean ± SD. *P < 0.05 compared with WT mice using ANOVA; internal comparisons were calculated by unpaired 
student t-test
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neuroinflammation in  Vps13a−/− mice, we evaluated 
expression of key autophagy flux proteins in isolated 
basal ganglia from saline buffer-perfused  Vps13a−/− and 
wild-type mice. Vps13a−/− basal ganglia exhibited acti-
vation of LC3  II/I and significant accumulation of the 
following autophagy-related proteins: Ulk1, Atg4, Atg5, 
Atg9 and the lysosomal cargo protein p62 consistent with 
impairment of autophagy in  Vps13a−/− mice (Additional 
file 1: Fig. S4A) as described in other neurodegenerative 
diseases such as PD and AD [45, 56–58]. The beclin-1 
system is one of the most critical hubs of the autophagic 
process, playing an important role in initiation and pro-
motion of autophagy. Severe neurodegeneration and 
impaired autophagy have been observed in  beclin1−/− 
mice, further linking beclin-1-dependent autophagy with 
neurodegenerative diseases [45, 58]. In  Vps13a−/− mice 
at 12 and 18  months of age, beclin-1 was significantly 
reduced as observed by different methods (Additional 
file  1: Fig. S4B, C). We also observed an accumulation 
of the beclin-1 complex components Vps34 and Rab5 as 
well as of p62, a marker of late phase of autophagy (Addi-
tional file 1: Fig. S5A). To further evaluate a possible link 
between chorein and beclin-1, we immunoprecipitated 
Beclin-1 and immunoblotted for either Chorein, Atg14L 
or Vps34. We found Chorein co-immunoprecipitated 
with Beclin-1 only in basal ganglia from wild-type mice 
but not from Vps13a−/− mice. In addition, we observed a 
reduction in Vps34 and Atg14L association with beclin-1 
in Vps13a−/− mice compared to wild-type animals (Addi-
tional file  1: Fig. S5B). Noteworthy, we found up-regu-
lation of beclin-1 mRNA levels in isolated basal ganglia 
from  Vps13a−/− mice compared to wild-type mice, sug-
gesting a Beclin-1 protein degradation (Additional file 1: 
Fig. S5C). Since Beclin-1 levels depend on Caspase 3 
activity, we evaluated Caspase-3 activation by immunob-
lot analysis of total cleaved Caspase-3 and a fluorometric 
assay for Caspase-3 activity. In basal ganglia of  Vps13a−/− 
mice, Caspase-3 activity was increased compared to wild-
type animals (Additional file 1: Fig. S5D). It is of note that 
increased Caspase-3 activity has been also reported in 
brains from PD patients [4, 19]. In  Vps13a−/− mice, the 
perturbation of autophagy resulted in accumulation of 
polyubiquitinated proteins in basal ganglia compared to 
wild-type animals, further supporting the impairment of 
autophagy in  Vps13a−/− mice (Additional file 1: Fig. S5E).
Vps13a−/−Lyn−/− mice show reduced acanthocytes, 
amelioration of autophagy and decreased activity of NF-kB 
p65, linked to neuroinflammation
To further explore the role of Lyn in  Vps13a−/− mice, we 
generated a  Vps13a−/−Lyn−/− double knockout mouse 
(Fig. 3 and Additional file 1: Fig. S6, S7). Since  Lyn−/− mice 
have been previously characterized and little role for Lyn 
kinase has been documented on primary neuronal func-
tions [17, 18], we focused on the comparison between 
 Vps13a−/− and  Vps13a−/−Lyn−/− mice. In addition, the 
hematologic phenotype of Lyn−/− mice of age less than 
15 months is similar to that of wild-type animals (Table S2) 
[25, 29]. In 12  months-old  Vps13a−/−  Lyn−/− mice, we 
observed significantly reduced acanthocyte numbers com-
pared to either Vps13a−/− or to Vps13a−/−Lyn−/+ mice. 
This finding was accompanied by (1) disappearance of the 
dense red cell fraction; (2) the reduction in HDW and (3) 
the reduction of red cell osmotic fragility in  Vps13a−/− 
 Lyn−/−mice compared to both  Vps13a−/− and  Vps13a−/− 
 Lyn−/+ mice (Fig.  3a, b, Additional file  1: Fig. S6A-B). 
Vps13a−/− mice genetically deficient in Lyn also exhib-
ited normalization of the red cell content of autophagy-
related proteins as compared to their elevated contents in 
Vps13a−/− mouse erythrocytes (Fig. 3c). In isolated basal 
ganglia from  Vps13a−/−  Lyn−/− mice, we found a slight but 
significant increase in beclin-1 and a marked reduction in 
accumulation of Vps34 and p62, supporting the dysregu-
lated autophagy in mice lacking chorein by the incremen-
tal absence of Lyn (Fig. 3d). Indeed, we further observed 
significantly reduced accumulation of polyubiquitinated 
proteins in the basal ganglia from  Vps13a−/−  Lyn−/− mice 
compared to  Vps13a−/− animals (Fig.  3e). This was asso-
ciated with reduced NF-kB p65 activation, suggesting a 
reduction in neuroinflammation in  Vps13a−/−  Lyn−/− 
mice (Fig. 3f). Collectively these data support a key role of 
Lyn in disease mechanism of ChAc.
Proteomic analyses of  Vps13a−/− mouse basal ganglia 
revealed abnormal proteostasis and accumulation 
of γ-synuclein
To understand the abnormal proteostasis in the basal 
ganglia of  Vps13a−/− mice, we carried out proteomic 
analysis of  Vps13a−/− mouse basal ganglia, using a 
label-free differential proteomic analysis based on 
Spectral Counts quantification, using Rsc method [75]. 
Among 3351 total identified proteins, 143 were selected 
as statistically significant changeable of which 69 were 
downregulated and 74 were upregulated compared to 
the basal ganglia of wild-type animals (Fig. 4a). Among 
the up-regulated proteins, we found of interest the fol-
lowing proteins for our model: (1) γ-Synuclein, member 
of the synuclein family; and (2) Synaptotagmins, which 
are involved in regulation of synaptic vesicle exocyto-
sis; and (3) Syntaxin-1, involved in synaptic transmis-
sion [6, 30, 47]. We confirmed the increased expression 
of γ-Synuclein and synaptotagmin in isolated basal 
ganglia from 12- and 18- months old  Vps13a−/− mice 
compared to wild-type animals (Fig.  4b). The accu-
mulation of γ-synuclein was also confirmed by 
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immunofluorescence microscopy (Fig. 4b, lower panel). 
The increased expression of γ-synuclein in basal gan-
glia from  Vps13a−/− mice is of specific note since mice 
genetically over-expressing γ-synuclein display an age-
dependent neurodegeneration, abnormal psycho-emo-
tional status and motor deficiency [47]. Increased levels 
of γ-synuclein have been reported in cerebrospinal fluid 
in Alzheimer disease (AD) patients, in individuals 
with Creutzfeld-Jakob disease [48], and may contrib-
ute to the pathogenesis of amyotrophic lateral sclerosis 
(ALS) [52]. We then asked whether the increase cellu-
lar levels of γ-synuclein might be associated with the 
accumulation of other neurotoxic proteins such as neu-
ronal microtubule-associated protein tau, which organ-
izes into pathogenic fibrils in phosphorylated form. We 
analyzed the Tau phospho-epitopes At8 and At180, 
which are reported to have functional importance in 
the neurodegeneration of Alzheimer’s disease [33]. 
In basal ganglia from  Vps13a−/− mice, we observed 
increased levels of At8 and At180 phosphorylated tau 
compared to wild-type animals (Fig. 4c). The accumula-
tion of phosphorylated At8 and At180 tau protein has 
been previously linked with Lyn activity in the context 
of AD [18]: Remarkably, neither γ-synuclein nor tau 
Fig. 3 Vps13−/−Lyn−/− mice show amelioration of hematologic phenotype and improvement of autophagy and neuroinflammation in basal 
ganglia. a Quantitation of acanthocytes by brightfield microscopic analysis of peripheral blood smears from Vps13a−/− and Vps13a−/−Lyn−/− mice. 
Data from 50 visual fields was collected by two blinded researchers. Results are means ± SEM n = 6; °p < 0.002 versus Vps13a−/− by t-test b Left panel. 
Red cell distribution histograms generated for red blood cell volume (RBC Volume) and cell haemoglobin concentration (RBC-HC) of RBCs from 
wild-type (WT) control, Vps13a−/−, Vps13a−/−Lyn−/− and Vps13a−/−Lyn−/+ mice. One representative experiment of six with similar results is shown.
The blue circle indicates the presence of a subpopulation of dense red cells containing acanthocytes, as described in human patients (Lupo et al. 
[42]). c Western blot (Wb) analysis of Ulk1 (Atg1) and Rab 5 from red cell cytosolic fractions of wild-type (WT), Vps13a−/− and Vps13a−/−Lyn−/− mice. 
Catalase was used as protein loading control. Densitometric analyses of the immunoblot bands similar to those shown are presented at right. 
Data are means ± SEM (n = 6; *P < 0.02 vs. WT; °P < 0.05 vs. Vps13a−/− by two-way-ANOVA/Bonferroni’s multiple comparison test). d Western blot 
(Wb) analysis of Beclin-1, Vps34 and p62 in isolated basal ganglia of wild-type (WT), Vps13a−/− and Vps13a−/−Lyn−/− mice. GAPDH served as protein 
loading control. Densitometric analyses of the immunoblot bands similar to those shown are presented at right. Data are means ± SEM (n = 6; 
*p < 0.02 vs. WT; °p < 0.02 compared to Vps13a−/− mice by two-way-ANOVA/Bonferroni’s multiple comparison test). e Western blot (Wb) analysis 
of K48-ubiquitinated proteins in basal ganglia isolated from wild-type (WT), Vps13a−/− and Vps13a−/−Lyn−/− mice. GAPDH served as protein 
loading control. Densitometric analyses of the immunoblot bands similar to those shown are presented at right. Data are means ± SEM (n = 6; 
*p < 0.02 vs. WT; °p < 0.02 compared to  Vps13a−/− mice by two-way-ANOVA/Bonferroni’s multiple comparison test). f Western blot (Wb) analysis 
of phospho-NF-kB p65 (P-NF-kB), NF-kB in isolated basal ganglia of wild-type (WT), Vps13a−/− and Vps13a−/−Lyn−/− mice. GAPDH served as protein 
loading control. Densitometric analyses of the immunoblot bands similar to those shown are presented at right. Data are means ± SEM (n = 6; 
*p < 0.02 vs. WT; °p < 0.02 compared to Vps13a−/− mice by two-way-ANOVA/Bonferroni’s multiple comparison test)
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phospho-epitopes At8 and 180 accumulated in isolated 
basal ganglia from  Vps13a−/−  Lyn−/− mice (Additional 
file  1: Fig. S7B-C). Taken together our evidence sug-
gests ChAc as a novel disorder of proteostasis related to 
impaired autophagy with accumulation of neurotoxic 
proteins, supporting the rational to target active Lyn as 
a novel therapeutic option for ChAc.
Dasatinib ameliorates hematologic but not neurologic 
disease markers in  Vps13a−/− mice
Since we tested dasatinib in our previous in  vitro stud-
ies, we administrated dasatinib (50 mg/kg once a day for 
4  weeks) to 12  months-old  Vps13a−/− mice. Dasatinib-
treated  Vps13a−/− mice developed mild anemia associ-
ated with a significant reduction in reticulocyte count 
(Hb vehicle: 14.6 ± 0.8 vs. Hb dasatinib: 10.3 ± 1.5  g/
dL; n = 8; p < 0.02; retic vehicle 390 ± 62 cell/µL vs. 
retic dasatinib: 201 ± 84 cell/µL  n = 6; p < 0.05). In 
 Vps13a−/− mouse RBCs, dasatinib markedly reduced the 
amount of active Lyn and improved autophagy as sup-
ported by the reduction of Ulk1 accumulation compared 
to vehicle treated animals (Additional file 1: Fig. S8A, B). 
However, basal ganglia of dasatinib-treated  Vps13a−/− 
mice revealed no major difference in accumulation of 
active Lyn nor in levels of beclin-1 or beclin-1 related 
proteins such as Vps34 or Rab 5, suggesting a lacking 
effect of dasatinib in the central nervous system (Addi-
tional file  1: Fig. S8C, D). Mass spectrometric analyses 
with detection limit of 0.01  pg/µl detected no dasatinib 
in basal ganglia (Additional file 1: Fig. S9, Table S3). We 
therefore reviewed the literature on Lyn inhibitors that 
have been previously reported to better cross the BBB 
[12, 21, 28, 49, 67]. We focused on nilotinib, a second-
generation TKI targeting Lyn, which has been previously 
shown to ameliorate mouse model phenotypes of PD and 
Fig. 4 Proteomic analysis of  Vps13a−/− mouse basal ganglia revealed accumulation of neurotoxic proteins related to impaired autophagy. a 
Heatmaps of statistically relevant identified proteins. Each line corresponds to a protein and each column is relative to a different sample. The 
different coloration is dependent on quantity of protein present in sample based on the statistical performed analysis. Specifically, red color refers 
to up-regulated proteins while green is associated to down-regulated proteins. The logarithm Fold Change scale is also reported. Panel A and panel 
B report proteins down-regulated and up-regulated in  Vps13a−/− mice compared to WT, respectively. b Upper panel. Western blot (Wb) analysis of 
γ-Synuclein, synaptotagmin and Rab 3 in isolated basal ganglia from 12 and 18 months (Mo) old wild-type and  Vps13a−/− mice. GAPDH was the 
protein loading control. Middle panel. Densitometric analyses of the immunoblot bands similar to those shown are presented in bar graph. Data 
are means ± SEM (n = 6; * P < 0.02 ChAc vs. WT by t-test). Lower panel. Representative confocal images of the γ-synuclein protein (green) in the 
striatum of WT and  Vps13a−/− mice at 18 months of age. Boxplots summarize the results presented as mean ± standard deviation (n = 3 animals for 
group; * P = 0.029). c Western blot (Wb) analysis of phopho-tau At8, At180, and total tau in isolated basal ganglia from 12 and 18 months (Mo) old 
wild-type and  Vps13a−/− mice. GAPDH was the protein loading control. Densitometric analyses of the immunoblot bands similar to those shown 
are presented at right. Data are means ± SEM (n = 6; *p < 0.02 vs. WT by t-test)
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Fig. 5 Nilotinib ameliorates  Vps13a−/− mouse red cell features and its passage into brain across the BBB prevents Lyn activation and improves 
autophagy. a Left panel. Quantitation of acanthocytes by brightfield microscopic analysis on  Vps13a−/− and  Vps13a−/− mice treated with nilotinib 
(25 mg/kg/d for 6 weeks). Data from 50 visual fields was collected by two blinded researchers. Results are means ± SEM n = 6; *P < 0.05 versus WT; 
°P < 0.05 versus vehicle treated  Vps13a−/− by 2-way ANOVA with Bonferroni correction for multiple comparison. Right panel. Red cell distribution 
histograms generated for red blood cell volume (RBC Volume) and cell hemoglobin concentration (RBC-HC) of RBCs from wild-type (WT) control, 
Vps13a−/− mice treated with nilotinib (25 mg/kg/d for 6 weeks). One experiment representative of six others with similar result is shown. The blue 
circle indicates the presence of a subpopulation of dense red cells, containing acanthocytes as described in human patients (see also Lupo et al. 
[42]). b Total Lyn was immunoprecipitated from red cell cytosol fractions of  Vps13a−/− mice treated with vehicle or with nilotinib (25 mg/kg/d for 
6 weeks (6Ws)) and detected with antibody against active Lyn (phospho-Lyn 396) or antibody against total Lyn (Wb: Western-blot). The experiment 
shown is representative of 6 experiments. IgG is used as loading control as catalase in whole cell lysate (WCL). Lower panel. Densitometric analysis 
of the immunoblots; means ± SEM (n = 6; P < 0.05 vs. WT by t-test). c Quantification of nilotinib in isolated basal ganglia from wild-type (WT) and 
Vps13a−/− mice treated either with vehicle or nilotinib. Data are means ± SD (n = 6; °P < 0.05 vs. vehicle treated  Vps13a−/− by 2-way ANOVA for 
multiple comparison). d Total Lyn was immunoprecipitated from basal ganglia of  Vps13a−/− mice treated with vehicle or with nilotinib (25 mg/
kg/d for 6 weeks (6Ws)). The experiment shown is representative of 6 experiments, each from an individual  Vps13a−/− mouse and each with similar 
results. IgG and catalase are used as loading control. WCL: whole cell lysate. Lower panel. Densitometric analysis of the immunoblots; means ± SEM 
(n = 6; °P < 0.05 vs. WT by t-test). e Total Lyn was immunoprecipitated from basal ganglia of wild-type and  Vps13a−/− mice treated with vehicle or 
with nilotinib (25 mg/kg/d for 6 months (6Mo), 12 months old mice) and detected with antibody against active Lyn (phospho-Lyn 396) or antibody 
against total Lyn (Wb: Western-blot). The experiment shown is representative of 6 experiments, each from an individual  Vps13a−/− mouse and 
each with similar results. IgG is shown as loading control as well as GAPDH in whole cell lysate (WCL). Lower panel. Densitometric analysis of the 
immunoblots; means ± SEM (n = 6; *P < 0.05 vs. WT; °P < 0.05 vs. vehicle treated  Vps13a−/− by 2-way ANOVA with Bonferroni correction for multiple 
comparison). f Western blot (Wb) analysis of Ulk1 (Atg1), Beclin-1, Vps34, Rab5, p62, phospho-tau At8, and At180 and total tau in isolated basal 
ganglia from 18 months old wild-type, and  Vps13a−/− mice treated with either vehicle or nilotinib (25 mg/kg/d for 6 months (6Mo)). GAPDH was 
used as loading control (See Additional file 1: Fig. 14S for data on nilotinib treated 12 months-old mice). Right panel. Densitometric analyses of 
the immunoblot bands similar to those shown are presented at right. Data are means ± SEM (n = 6; *P < 0.05 vs. WT; °P < 0.05 vs. vehicle treated 
 Vps13a−/− by 2-way ANOVA with Bonferroni correction for multiple comparison). g Western blot (Wb) analysis of γ-Synuclein and Synaptotagmin in 
isolated basal ganglia from 12 months old wild-type, and  Vps13a−/− mice treated with either vehicle or nilotinib (25 mg/kg/d for 3 months (3Mo)) 
and 18 months old wild-type, and  Vps13a−/− mice treated with either vehicle or nilotinib (25 mg/kg/d for 6 months (6Mo)). GAPDH was used as 
loading control. Lower panel. Densitometric analyses of the immunoblot bands similar to those shown are presented. Data are means ± SEM (n = 6; 
*P < 0.05 vs. WT; °P < 0.05 vs. vehicle treated  Vps13a−/− by 2-way ANOVA with Bonferroni correction for multiple comparison)
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AD by improving autophagy [12, 21, 28], and has tested 
in 6 months phase II clinical trial in PD patients [49, 62].
Nilotinib reduces acanthocytosis, improves autophagy 
and neuroinflammation in basal ganglia from  Vps13a−/− 
mice
In  Vps13a−/− mice, nilotinib (1) markedly reduced acan-
thocytosis and dense red cell fraction (Fig.  5a, Addi-
tional file  1: Fig. S10A); (2) prevented the accumulation 
of active Lyn in  Vps13a−/− mouse RBCs (Fig. 5b); and (3) 
normalized RBC autophagy related proteins Ulk1 and 
Atg7 accumulation (Additional file  1: Fig. S10B). Nilo-
tinib was detected by LC–MS/MS spectrometric analysis 
in basal ganglia from WT and Vps13a−/− mice (Fig. 5c, 
Additional file  1: Fig. S10C, Table  S4). The presence of 
nilotinib in Vps13a−/− mouse basal ganglia was associ-
ated with markedly reduced basal ganglia accumulation 
of active Lyn after nilotinib treatment for 6 weeks or for 
6 months (Fig. 5d, e). Accumulation of the key autophagy-
related proteins Ulk1, Vps34, Rab5 and p62 were also 
reduced in basal ganglia of mice treated with nilotinib for 
either 6 weeks or 6 months (Fig. 5f, Additional file 1: Fig. 
S10D). Noteworthy, increased Vps13a−/− mouse basal 
ganglia beclin-1 levels were noted only after 6  months’ 
nilotinib treatment (Fig. 5f, Additional file 1: Fig. S10D). 
Accumulation of phospho-tau At8 and At180 (Fig.  5f, 
Additional file 1: Fig. S10E), γ-synuclein and synaptotag-
min (Fig.  5g) were prevented by nilotinib treatment in 
basal ganglia from Vps13a−/− mice. Finally, we evaluated 
the impact of long-term treatment (3–6 months) on neu-
roinflammation in  Vps13a−/− mice. As shown in Fig. 6a, 
b and Additional file 1: Fig. S11, we observed a significant 
reduction in microglia associated with decreased acti-
vated NF-kB p65 in both cortex and basal ganglia. Taken 
Fig. 6 Nilotinib decreases neuroinflammation in  Vps13a−/− mice. a Representative images of Iba-1 positive microglia cells in cortex of  Vps13a−/− 
mice treated with vehicle or with nilotinib (25 mg/kg/d for 6 months) (Microglia in red, nuclei in blue). Scale bar:50 mm. Quantitative analyses show 
significant differences in microglial density and activation in the cortex of  Vps13a−/− vehicle compared to treated mice. Results are expressed as 
mean ± SEM (*P < 0.05; ****P < 0.0001; Unpaired t-test). b Western blot (Wb) analysis of phospho-NF-kB p65 and NF-kB p65 in the cortex (left panel) 
and in isolated basal ganglia (right panel) from 12 and 18 months (Mo) old wild-type mice and  Vps13a−/− animals treated with vehicle or with 
nilotinib (25 mg/kg/d for 3 months (3Mo) and 6 months (6Mo) respectively). GAPDH was the protein loading control. Lower panel. Densitometric 
analyses of the immunoblot bands similar to those shown are presented. Data are means ± SEM (n = 6; ^P < 0.05 vs. 12 months old mice; °P < 0.05 
vs. vehicle treated  Vps13a−/− by 2-way ANOVA with Bonferroni correction for multiple comparison). c Mice genetically lacking chorein  (Vps13a−/−) 
display phenotype similar to patients with chorea-acanthocytosis (ChAc). We show protein accumulation and impaired autophagy in both red 
cells and basal ganglia from  Vps13a−/− mice. This is associated with neuronal loss, neuroinflammation and generation of circulating acanthocytes. 
Tyrosine kinase inhibitors (TKI) targeting Lyn kinase have been tested in  Vps13a−/− mice. Nilotinib but not dasatinib reduces protein accumulation 
and ameliorates autophagy with reduction in neuronal loss and neuroinflammation as well as in circulating acanthocytes. Atgs: autophagy related 
proteins
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together, our data support the accumulation of active 
Lyn and impaired autophagy as possible therapeutic tar-
gets for clinical intervention in ChAc. We demonstrated 
that nilotinib crosses the BBB, improves autophagy and 
reduces neuroinflammation in a mouse model for ChAc.
Discussion
ChAc is a rare, progressive, multisystem neurodegenera-
tive disease of young adulthood with no available treat-
ment to halt or retard its devastating progression out. 
The identification of new therapeutic option(s) target-
ing disease mechanism(s) represents an urgent unmet 
need in ChAc. We first characterized Vps13a−/− mice in 
order to advance understanding of ChAc and to search 
for additional drug targets and novel drug candidates. 
 Vps13a−/− mice display (1) acanthocytes; (2) signs of 
both hyper- and hypokinetic movement disorders; (3) 
accumulation of active Lyn and of autophagy-related 
proteins in RBCs; and (4) RBC retention of remnants of 
double membrane and multivesicular bodies. Abnormali-
ties in motor behavior observed in  Vps13a−/− mice cor-
relate with the movement disorders, specifically dystonia, 
seen in ChAc patients [50, 70]. Indeed, the neurologic 
phenotype of Vps13a−/− mice resembles that of another 
mouse model for ChAc carrying a deletion of exons 
60–61. [66]. In isolated basal ganglia of  Vps13a−/− mice, 
we found signs of neurodegeneration associated with (1) 
accumulation of Lyn, stabilized in high molecular weight 
complexes; (2) accumulation of autophagy related pro-
teins; and (3) reduction in expression of beclin-1, a key 
initiator of autophagy, due to increased caspase 3 activ-
ity. Normalization of phenotypes in the Vps13a−/−Lyn−/− 
double knock out model substantiates the central role 
of accumulation of active Lyn in the pathophysiology 
of ChAc. Lyn has been previously reported to contrib-
ute to varied neuronal functions throughout the phos-
phorylation of key substrates such as NMDA or AMPA 
receptors [16, 41, 59]. In addition, in  vitro studies also 
suggest that active Lyn might reduce or alter exocytosis 
by phosphorylation of both proteins of synaptic vesicles 
and actin cytoskeleton [16]. Lyn and Src family kinases 
have been also shown to participate in autophagy by tar-
geting various autophagy-related proteins such as Ulk1 
[36, 37, 42]. However, the accumulation of active Src 
family kinases might be per se cytotoxic, contributing to 
impaired autophagy as reported in cancer cells [72, 73] 
The accumulation of At8- and At180-phosphorylated tau 
proteins and γ-synuclein as well as of polyubiquinated 
proteins in  Vps13a−/− mouse basal ganglia is consistent 
with abnormal autophagy in the absence of chorein. Our 
data adds ChAc, for the first time, to the group of clas-
sical neurodegenerative proteinopathies such as AD, PD 
and HD. These three diseases are also characterized by 
abnormalities in autophagy as well as by reduced beclin-1 
[58, 61, 63]. In addition, recent reports of severe neuro-
degeneration and impairment of autophagy in  beclin1−/− 
mice further links beclin-1-dependent autophagy to 
neurodegenerative diseases [45, 55, 65]. In particular, the 
beclin-1-Vps34 complex is critical for autophagosome 
formation, subsequently involving Atg14 with recruit-
ment of Rab 5 [45, 58]. In  Vps13a−/− mice, the absence 
of chorein results in impairment of beclin-1 pathway 
with accumulation of Vps34, Atg14 and Rab5, suggest-
ing a perturbation of protein trafficking associated with 
possible abnormalities in maturation and/or degrada-
tion of autophagosomes. This is further supported by 
the association between chorein with beclin-1 observed 
in basal ganglia from wild-type mice. Although chorein 
does not contain a recognized actin-binding motif, it 
carries a coil-coil binding motif that may be involved in 
beclin-1 interactions. A complex connection has been 
reported between beclin-1 and inflammation [24, 46]. 
In  vitro studies show that block of autophagy results in 
up-regulation of pro-inflammatory cytokines such as 
IL-1β [24, 46]. Here, we found neuroinflammation in 
 Vps13a−/− mice associated with activation of NF-kB p65 
and increased expression of IL-1β further emphasizing 
similarities between ChAc and other neurodegenerative 
disorders characterized by abnormal proteostasis such 
as PD or AD [15]. At this stage we cannot determine 
whether neuroinflammation is directly involved in the 
etiology of ChAc or indirectly related to the neurode-
generative processes in the basal ganglia. Although sys-
tematic investigation of ChAc neuropathology in human 
brains is still lacking, preliminary reports on brain from 
patients with ChAc suggests the presence of microgliosis 
[38, 39, 50].
Collectively these findings led us to test in our mouse 
ChAc model a Lyn kinase inhibitor that crosses the 
BBB more easily than dasatinib. Nilotinib beneficially 
impacts ChAc mouse hematological phenotype and 
improves ChAc RBC features. Furthermore, nilotinib 
was detected in basal ganglia from  Vps13a−/− mice 
resulting in improvement of autophagy with reduction 
of active Lyn and accumulation of autophagy related 
proteins. Vps13a−/− mice treated long-term with nilo-
tinib exhibited increased levels of basal ganglia bec-
lin-1, associated with reduced microglia density and 
reduced active NF-kB p65. These data further sup-
ported the link between beclin-1 dependent autophagy 
and inflammation in ChAc mice.
In conclusion, our data show for the first time that 
the pathogenesis of ChAc is linked to perturbation of 
beclin-1 pathway, resulting in impaired autophagy 
with accumulation of active Lyn and classic neuro-
toxic proteins such as γ-synuclein or phospho-tau 
Page 12 of 15Peikert et al. acta neuropathol commun            (2021) 9:81 
At8 and  At180. Abnormal autophagy contributes to 
NF-kB activation and expression of pro-inflammatory 
cytokines, such as Il-1b, in combination with microglia 
activation, sustaining a neuroinflammatory environ-
ment in ChAc as in other neurodegenerative disor-
ders such as PD or AD. Our data prove active Lyn to 
be a key regulator of neurodegeneration in ChAc, thus 
generating a rationale to consider TKIs targeting Lyn 
per se as possible and safe novel therapeutic approach 
for ChAc  patients (Fig.  6c). Our results propose BBB-
permeable Lyn kinase inhibitors such as nilotinib as 
first-line treatment options for patients suffering from 
ChAc. As nilotinib is already in clinical use for treat-
ment of other diseases [21], larger-scale studies of 
nilotinib for treatment of ChAc should be eligible for 
accelerated approval. Our data support the proposal 
to repurpose nilotinib as new therapeutic option for 
ChAc.
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